We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+69.32%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$408M
AUM Growth
+$136M
Cap. Flow
+$68.1M
Cap. Flow %
16.68%
Top 10 Hldgs %
29.1%
Holding
175
New
29
Increased
78
Reduced
38
Closed
27

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$8.17M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.71M
3
INSM icon
Insmed
INSM
+$4.7M
4
CDTX
Cidara Therapeutics
CDTX
+$4.52M
5
ACLX
Arcellx
ACLX
+$4.35M

Top Sells

Rank Stock Value
1
ANSS
Ansys
ANSS
+$6.01M
2
JNPR
Juniper Networks
JNPR
+$4.58M
3
HES
Hess
HES
+$4M
4
AMED
Amedisys
AMED
+$3.86M
5
WDC icon
Western Digital
WDC
+$2.97M

Sector Composition

Rank Sector Weight
1 Healthcare 59%
2 Technology 12.01%
3 Industrials 6.97%
4 Financials 4.64%
5 Consumer Discretionary 3.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PBR.A icon
76
Petrobras Class A
PBR.A
$103B
$1.63M 0.4%
138,200
+33,200
+32% +$384K
STX icon
77
Seagate
STX
$186B
$1.63M 0.4%
6,898
-15,202
-69% -$2.59M
APG icon
78
APi Group
APG
$18.5B
$1.63M 0.4%
47,350
+9,625
+26% +$336K
MDGL icon
79
Madrigal Pharmaceuticals
MDGL
$12.4B
$1.62M 0.4%
3,537
+1,232
+53% +$460K
CNTA
80
DELISTED
Centessa Pharmaceuticals
CNTA
$1.54M 0.38%
63,301
+22,617
+56% +$402K
CNM icon
81
Core & Main
CNM
$8.73B
$1.5M 0.37%
+27,900
New +$1.69M
ROIV icon
82
Roivant Sciences
ROIV
$25.5B
$1.5M 0.37%
98,858
+37,590
+61% +$465K
CRBP icon
83
Corbus Pharmaceuticals
CRBP
$184M
$1.49M 0.37%
118,027
+42,735
+57% +$406K
CSCO icon
84
Cisco
CSCO
$475B
$1.49M 0.37%
21,800
-1,800
-8% -$123K
INTU icon
85
Intuit
INTU
$92B
$1.48M 0.36%
2,163
-1,100
-34% -$793K
TARS icon
86
Tarsus Pharmaceuticals
TARS
$3.05B
$1.48M 0.36%
24,854
+13,174
+113% +$649K
ENTG icon
87
Entegris
ENTG
$23B
$1.45M 0.36%
15,700
-5,200
-25% -$442K
RDDT icon
88
Reddit
RDDT
$30.1B
$1.45M 0.36%
+6,300
New +$1.29M
MTZ icon
89
MasTec
MTZ
$21.9B
$1.43M 0.35%
6,700
-4,300
-39% -$787K
BAC icon
90
Bank of America
BAC
$448B
$1.42M 0.35%
27,500
-5,100
-16% -$249K
ASND icon
91
Ascendis Pharma A/S
ASND
$16.7B
$1.41M 0.35%
7,082
+4,108
+138% +$766K
ADMA icon
92
ADMA Biologics
ADMA
$2.22B
$1.39M 0.34%
+95,112
New +$1.63M
EOLS icon
93
Evolus
EOLS
$551M
$1.39M 0.34%
226,025
+167,983
+289% +$1.31M
RBC icon
94
RBC Bearings
RBC
$17.5B
$1.37M 0.33%
3,500
-200
-5% -$77.9K
OFIX icon
95
Orthofix Medical
OFIX
$420M
$1.36M 0.33%
93,200
-13,300
-12% -$175K
PGR icon
96
Progressive
PGR
$123B
$1.36M 0.33%
5,500
-400
-7% -$98.6K
JANX icon
97
Janux Therapeutics
JANX
$1.01B
$1.35M 0.33%
55,250
-7,186
-12% -$175K
CORZ icon
98
Core Scientific
CORZ
$6.35B
$1.35M 0.33%
75,163
-104,737
-58% -$1.54M
SCHW
99
Charles Schwab
SCHW
$186B
$1.35M 0.33%
14,100
-2,200
-13% -$209K
ALKS icon
100
Alkermes
ALKS
$8.26B
$1.32M 0.32%
44,081
-8,863
-17% -$250K
2 3
4
5 6

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

HighVista Strategies's Q3 2025 Portfolio in Review

As of Q3 2025, HighVista Strategies held 175 positions worth $408M, up 50% from $272M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

HighVista Strategies deployed $68.1M of net new capital in Q3 2025, opening 29 new positions and adding to 78 existing holdings. Its largest new stake was Cidara Therapeutics: 70,904 shares worth $6.79M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, up from 38% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Western Digital, an estimated $2.97M trimmed.

  • HighVista Strategies's largest Q3 2025 buy was Cidara Therapeutics: 70,904 shares worth $6.79M.
  • HighVista Strategies added most to Abivax in Q3 2025, an estimated $8.17M increase.
  • HighVista Strategies's biggest Q3 2025 reduction was Western Digital, cutting an estimated $2.97M.
  • HighVista Strategies fully exited Ansys in Q3 2025, selling an estimated $6.01M.
  • HighVista Strategies's ten largest holdings make up 29% of its $408M portfolio in Q3 2025.
  • HighVista Strategies opened 29 new positions and closed 27 in Q3 2025.
  • HighVista Strategies's portfolio value rose 50% quarter-over-quarter to $408M.

Based on HighVista Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.